Daiichi Sankyo (OTCMKTS:DSNKY) Issues FY 2026 Earnings Guidance

Key Points

• Daiichi Sankyo updated its FY 2026 guidance, projecting EPS of 0.910 versus the consensus estimate of 1.040. The company kept revenue guidance at $14.5 billion, above the $13.4 billion analyst consensus.
• The stock rose 1.8% on the announcement, trading at $16.80 with volume well below its average. The shares remain below both their 50-day and 200-day moving averages.
• Analyst sentiment is mixed but positive overall, with Zacks Research upgrading the stock from strong sell to hold and MarketBeat data showing a consensus rating of Buy.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided EPS guidance of 0.910-0.910 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $14.5 billion-$14.5 billion, compared to the consensus revenue estimate of $13.4 billion.

Daiichi Sankyo Stock Up 1.8%

OTCMKTS DSNKY traded up $0.29 during trading on Monday, reaching $16.80. 32,410 shares of the company's stock were exchanged, compared to its average volume of 444,342. Daiichi Sankyo has a fifty-two week low of $15.56 and a fifty-two week high of $28.21. The company's fifty day simple moving average is $17.94 and its 200-day simple moving average is $20.47. The company has a current ratio of 2.69, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $31.83 billion, a PE ratio of 15.41, a P/E/G ratio of 0.85 and a beta of -0.25.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Daiichi Sankyo from a "strong sell" rating to a "hold" rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy".

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.